Alaunos Therapeutics (TCRT) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with TCRT. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

All figures are approximate and tied to the asOf date; verify live numbers before acting, because a company in this condition can change rapidly through conversion, a reverse split, further financing, or listing decisions. The quoted market value of about $7 million reflects the old share count and does not capture the roughly 358.6 million as-converted shares expected after the Velaris deal, so screen-based valuation figures are misleading until the share count is updated. Traditional valuation is not meaningful for a company with no revenue whose value now rests on early pulmonary hypertension programs.

No analyst publishes estimates on TCRT, so these are the most recent figures we hold, as of October 2026. They describe where the company stands, not where it is going.

• Revenue: Essentially none (about $3,000 trailing twelve months); no product revenue
• Net loss (TTM): ~$4.1 million
• Cash (June 30, 2026): ~$124,000, before the October 2026 financing
• October 2026 financing: ~$350 million Series C convertible preferred private placement led by Fairmount; runway expected into 2029
• Share count after deal: ~358.6 million as-converted (subject to stockholder vote)
• Market cap (Oct 16, 2026): ~$7 million at $2.47 on the pre-conversion share count
• Analyst coverage: None in Yahoo Finance's data; the stock trades on deal news and speculation

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering TCRT do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Alaunos Therapeutics can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Velaris and the pulmonary hypertension pipeline, A funded balance sheet after years of near-insolvency, Obesity program (ALN1003) and the legacy hunTR platform. The risk cited most often against it is the risks remain severe, though their nature has shifted.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the TCRT is it a buy page. This page deliberately stops at the numbers.